Immunocore has appointed Andrew Hotchkiss as chief commercial officer. Andrew joins from Eli Lilly & Co, where he held a number of global leadership positions across multiple therapeutic areas and geographies including as VP international business unit leader oncology and president biomedicines business units, Australia, Canada and Europe.